Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
MT newswire2026/10/05 13:1409:14 AM EDT, 10/05/2026 (MT Newswires) -- Prime Medicine (PRME) has dosed its first patient in a phase 1/2 clinical trial of PM577a, an investigational in vivo treatment for H1069Q-mutated Wilson disease, the company said Monday. The study will initially enroll adults who are clinically stable and being treated with standard-of-care therapy, the company said. Initial clinical data are expected next year, the company added. The biotechnology company also said the US Food and Drug Administration has granted Rare Pediatric Disease designation to PM577 for Wilson disease. Wilson disease is a rare, progressive genetic disorder which leads to copper accumulation in the liver, followed by damage to other organs, the company said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
Crypto prices
More
